Response Rate & Risk Profile: Interpreting Early Efficacy in High-Risk mTNBC Patients

Early relapse patterns reveal a high-risk patient population — and that context matters when interpreting trial outcomes. Dr. Garrido-Castro explains how DFI, brain metastases, and biology shaped the differences between the two studies.

She also breaks down the major response-rate gap: dato-DXd at 63% vs 29% with chemotherapy, and why rapid responses may be critical in patients with visceral disease.